(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s ...
In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...
Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results